Open AccessThe TPM3‐NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition
Author(s) -
Ardini Elena,
Bosotti Roberta,
Borgia Andrea Lombardi,
De Ponti Cristina,
Somaschini Alessio,
Cammarota Rosaria,
Amboldi Nadia,
Raddrizzani Laura,
Milani Andrea,
Magnaghi Paola,
Ballinari Dario,
Casero Daniele,
Gasparri Fabio,
Banfi Patrizia,
Avanzi Nilla,
Saccardo Maria B.,
Alzani Rachele,
Bandiera Tiziano,
Felder Eduard,
Donati Daniele,
Pesenti Enrico,
Sartore-Bianchi Andrea,
Gambacorta Marcello,
Pierotti Marco A.,
Siena Salvatore,
Veronese Silvio,
Galvani Arturo,
Isacchi Antonella
Publication year - 2014
Publication title -
molecular oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.332
H-Index - 88
eISSN - 1878-0261
pISSN - 1574-7891
DOI - 10.1016/j.molonc.2014.06.001
Subject(s) - tropomyosin receptor kinase a , cancer research , biology , kinase , microbiology and biotechnology , receptor , nerve growth factor , genetics
The NTRK1 gene encodes Tropomyosin‐related kinase A (TRKA), the high‐affinity Nerve Growth Factor Receptor. NTRK1 was originally isolated from a colorectal carcinoma (CRC) sample as component of a somatic rearrangement (TPM3‐NTRK1) resulting in expression of the oncogenic chimeric protein TPM3‐TRKA, but there has been no subsequent report regarding the relevance of this oncogene in CRC. The KM12 human CRC cell line expresses the chimeric TPM3‐TRKA protein and is hypersensitive to TRKA kinase inhibition. We report the detailed characterization of the TPM3‐NTRK1 genomic rearrangement in KM12 cells and through a cellular screening approach, the identification of NMS‐P626, a novel highly potent and selective TRKA inhibitor. NMS‐P626 suppressed TPM3‐TRKA phosphorylation and downstream signaling in KM12 cells and showed remarkable antitumor activity in mice bearing KM12 tumors. Finally, using quantitative reverse transcriptase PCR and immunohistochemistry (IHC) we identified the TPM3‐NTRK1 rearrangement in a CRC clinical sample, therefore suggesting that this chromosomal translocation is indeed a low frequency recurring event in CRC and that such patients might benefit from therapy with TRKA kinase inhibitors.